201 related articles for article (PubMed ID: 34868027)
1. Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant.
Cheong Y; Kim M; Ahn J; Oh H; Lim J; Chae W; Yang SW; Kim MS; Yu JE; Byun S; Jang YH; Seong BL
Front Immunol; 2021; 12():769088. PubMed ID: 34868027
[TBL] [Abstract][Full Text] [Related]
2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
3. Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.
Skibinski DA; Hanson BJ; Lin Y; von Messling V; Jegerlehner A; Tee JB; Chye de H; Wong SK; Ng AA; Lee HY; Au B; Lee BT; Santoso L; Poidinger M; Fairhurst AM; Matter A; Bachmann MF; Saudan P; Connolly JE
PLoS One; 2013; 8(10):e76571. PubMed ID: 24204639
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
6. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
8. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
9. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
10. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
[TBL] [Abstract][Full Text] [Related]
12. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
[TBL] [Abstract][Full Text] [Related]
13. Influence of adjuvants on the amount, specificity and functional activity of antibody response to human influenza vaccine in mice.
Voutssas-Lara J; Cervantes-Torres J; Hernández M; Bobes RJ; Lamoyi E; Vázquez-Ramírez RA; Mendoza L; Reyes-Barrera KL; López-Martínez R; Alpuche-Solís ÁG; Rosales-Mendoza S; Huerta L; Fragoso G; Sciutto E
Mol Immunol; 2021 Jul; 135():398-407. PubMed ID: 34022515
[TBL] [Abstract][Full Text] [Related]
14. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
15. Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.
Nguyen QT; Kwak C; Lee WS; Kim J; Jeong J; Sung MH; Yang J; Poo H
Front Immunol; 2019; 10():1604. PubMed ID: 31354739
[TBL] [Abstract][Full Text] [Related]
16. Vaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity.
Bayne AC; Boltz D; Owen C; Betz Y; Maia G; Azadi P; Archer-Hartmann S; Zirkle R; Lippmeier JC
PLoS One; 2013; 8(4):e61790. PubMed ID: 23626728
[TBL] [Abstract][Full Text] [Related]
17. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
Front Immunol; 2020; 11():1207. PubMed ID: 32636840
[TBL] [Abstract][Full Text] [Related]
18. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates.
Pan W; Han L; Dong Z; Niu X; Li Z; Bao L; Li C; Luo Q; Yang Z; Li X; Huang J; Feng L; Qin C; Zhong N; Chen L
Antiviral Res; 2014 Jul; 107():1-5. PubMed ID: 24746458
[TBL] [Abstract][Full Text] [Related]
19. Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines.
Sanchez PL; Staats HF; Abraham SN; Ross TM
Sci Rep; 2024 Jun; 14(1):13800. PubMed ID: 38877101
[TBL] [Abstract][Full Text] [Related]
20. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
Morçӧl T; Hurst BL; Tarbet EB
Vaccine; 2017 Aug; 35(35 Pt B):4569-4577. PubMed ID: 28716554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
